SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001493152-23-037735
Filing Date
2023-10-19
Accepted
2023-10-19 17:18:34
Documents
3
Period of Report
2023-10-19

Document Format Files

Seq Description Document Type Size
1 formpre14a.htm PRE 14A 416404
2 formpre14a_001.jpg GRAPHIC 251271
3 formpre14a_002.jpg GRAPHIC 229324
  Complete submission text file 0001493152-23-037735.txt   1079559
Mailing Address JFL CAPITAL MANAGEMENT 1017 RR 620 S, SUITE 107 LAKEWAY TX 78734
Business Address JFL CAPITAL MANAGEMENT 1017 RR 620 S, SUITE 107 LAKEWAY TX 78734 737 203 5270
Anebulo Pharmaceuticals, Inc. (Filer) CIK: 0001815974 (see all company filings)

IRS No.: 851170950 | State of Incorp.: DE | Fiscal Year End: 0630
Type: PRE 14A | Act: 34 | File No.: 001-40388 | Film No.: 231335461
SIC: 2834 Pharmaceutical Preparations